A major limitation of current humanized mouse models is that they primarily enable the analysis of human-specific pathogens that infect hematopoietic cells. However, most human pathogens target other cell types, including epithelial, endothelial and mesenchymal cells. Here, we show that implantation of human lung tissue, which contains up to 40 cell types,
A lthough in vivo animal models exist for many clinically relevant and emerging human pathogens [1] [2] [3] [4] , they currently all lack biologically relevant human cells, which limits our ability to study pathogen replication, pathogenesis, immune responses and sensitivity to therapeutics in vivo. In vivo animal models with natural human target cells for infection are needed to accelerate the development and testing of effective vaccines and therapeutics for many highly relevant human pathogens such as human cytomegalovirus (HCMV), human respiratory syncytial virus (RSV) and Mycobacterium tuberculosis, in addition to many emerging pathogens 1 , all of which cause substantial global mortality and morbidity [5] [6] [7] [8] [9] .
Although commonly used, inbred mouse strains do not faithfully recapitulate important aspects of human disease and the human immune response 10 . Furthermore, many human pathogens do not replicate in wild-type mice 1, 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The availability of highly immunodeficient mouse strains allows for the creation of human/ mouse chimeric models (humanized mice) that are locally or systemically reconstituted with human hematopoietic cells following engraftment of human tissues and/or stem cells. Humanized mice have been used to study human immune development and human-specific pathogens that replicate in human hematopoietic cells (for example, Epstein-Barr virus, dengue virus, human immunodeficiency virus, Kaposi's sarcoma herpesvirus) and to test the efficacy of preventative and therapeutic agents 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] 22, 23 . Bone marrow/liver/thymus (BLT) humanized mice are generated by bone marrow transplantation of immunodeficient mice implanted with autologous human thymus/liver tissue. BLT mice are systemically reconstituted with human innate (monocytes/macrophages, dendritic cells, natural killer (NK) cells) and adaptive (B and T cells) immune cells. The presence of a human thymic organoid in the BLT model allows for human T-cell education on human leukocyte antigens (HLA) and the induction of HLA-restricted T-cell responses consistent with those observed in humans 14, 24, 25 .
The applications of current humanized mouse models for biomedical research would be significantly broadened by the inclusion of human nonhematopoietic cell types, the primary targets of most human pathogens, which can present antigen to autologous human immune cells in the full context of HLA 5, 9, [26] [27] [28] [29] . The human lung contains up to 40 different cell types including epithelial, endothelial, mesenchymal and smooth muscle cells 30 and it is an important natural site of pathogen replication 9, 26, [31] [32] [33] [34] . We implanted human lung tissue subcutaneously into the back of immunodeficient mice to create humanized lung-only mice (LoM). The human lung tissue vascularizes, expands and persists as a human lung implant, and supports replication of viral and bacterial human pathogens in vivo. When incorporated into BLT mice (BLT-lung (BLT-L) mice), lung implants are repopulated with autologous human innate and adaptive immune cells. Direct inoculation of BLT-L human lung implants with HCMV induces HCMV-specific human IgM,
IgG and T-cell responses which can effectively control infection
LoM support infection of a broad range of human pathogens. Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging human pathogen that targets the human lung 26 but which does not infect mice, ferrets or hamsters due to genetic differences in its receptor, dipeptidyl peptidase 4 (DPP4) 1, 20, 21 . MERS-CoV was inoculated directly into the human lung implants of LoM. MERS-CoV titers (mean 2.02 × 10 8 ± 1.08 × 10 8 s.e.m. plaque-forming units (PFU) ml −1 g −1; range 1.2 × 10 6 -8.09 × 10 8 PFU ml −1 g −1 ) in the human lung implants 48 h later were 3 logs higher than the inoculum (Fig. 2a) . The presence of MERS-CoV antigen in human epithelial, endothelial and mesenchymal cells indicated that MERS-CoV has broad cellular tropism in vivo ( Fig. 2b) . At a lower inoculum (10 4 PFU), MERS-CoV replication was variable but still readily detectable (mean 2.29 × 10 8 ± 2.09 × 10 8 s.e.m. PFU ml −1 g −1; range1.92 × 10 3 -8.57 × 10 8 PFU ml −1 g −1 ) ( Fig. 2a ).
Zika virus (ZIKV) has been detected in human neonatal lungs and shown to infect human lung cell lines in vitro 31, 39 . In wild-type mice, the type 1 interferon response suppresses ZIKV infection 2 . Human lung implants of LoM inoculated with ZIKV and assayed 48 h later contained robust levels of cell-associated ZIKV RNA (mean 1.37 × 10 4 ± 5.91 × 10 3 s.e.m. ZIKV RNA copies per 10 5 cells; range 5.21 × 10 3 -2.42 × 10 4 ZIKV RNA copies per 10 5 cells) ( Fig. 2c ). ZIKV antigen was detected in human epithelial and mesenchymal cells (Fig. 2d ). Similar to MERS-CoV, at a lower inoculum (10 3 focus-forming units (FFU)), ZIKV RNA levels were variable but readily detectable (mean 2.65 × 10 3 ± 1.47 × 10 3 s.e.m. ZIKV RNA copies per 10 5 cells; range 2.7 × 10 1 -6.83 × 10 3 ZIKV RNA copies per 10 5 cells) ( Fig. 2c ).
We inoculated Mycobacterium bovis Bacillus Calmette-Guérin (BCG), the attenuated live vaccine strain of M. tuberculosis, into the human lung implants of LoM. Bacterial burden was assessed by colony formation (colony forming units, c.f.u.). BCG levels in human lung implants of LoM 28 d postexposure (mean 3.40 × 10 5 ± 1.20 × 10 5 s.e.m. c.f.u.; range 1.03 × 10 5 -4.95 × 10 5 c.f.u.) were 8.5-fold higher than the inoculum (4 × 10 4 c.f.u.) ( Fig. 2e ). BCG also replicated in the human lung implants of LoM receiving a 100-fold lower inoculum (4 × 10 2 c.f.u.); the bacterial burden (mean 2.57 × 10 4 ± 1.53 × 10 4 s.e.m. c.f.u.; range 3.10 × 10 3 -5.49 × 10 4 c.f.u.) was 65-fold higher than the inoculum. Acid-fast staining confirmed diffuse clusters of bacteria within the human lung implants (Fig. 2f ).
We inoculated LoM implants with RSV expressing green fluorescent protein (GFP). At 4 d post-RSV inoculation, GFP-positive cells indicative of RSV infection and replication were detected in the human lung implants (mean 144.38 ± 41.53 s.e.m. GFP + cells per 10 5 total cells; range 35-333 GFP + cells per 10 5 total cells) ( Fig. 2g ). Infection of human airway epithelial cells in vitro and in vivo with RSV is characterized by extrusion of infected cells into the airway lumen and loss of cilia from infected ciliated cells 40 . Consistent with these observations, RSV-infected cells were observed protruding and shedding from the epithelial cell layer into the lumen ( Fig. 2h ) and they lacked costaining for cilia ( Fig. 2i ). Large deposits of mucin were also noted in the airways of RSV-infected lung implants ( Fig. 2j ) as has been observed in the lungs of RSV-infected children 41 .
HCMV is a ubiquitous human-specific pathogen that does not replicate in other species 5 . We injected cell-free HCMV TB40/E, a clinical HCMV strain, into the human lung implants of LoM. HCMV DNA was detected in the lung implants of LoM as early as 4 d postinoculation (mean 4.70 × 10 3 ± 2.54 × 10 3 s.e.m. HCMV DNA copies per 10 5 cells; range 2.94 × 10 2 -1.19 × 10 4 HCMV DNA copies per 10 5 cells) ( Fig. 2k ). HCMV immediate early (IE), early and late proteins were detected in lung implants at 14 d and 52 d postinoculation indicating that HCMV infection was maintained over time ( Fig. 2l ). The expression of IE proteins is consistent with lytic HCMV replication in this model as observed during human primary infection and reactivation 42 . In vivo, HCMV antigen was observed in human mesenchymal cells ( Fig. 2m ). We determined the effect of preexposure prophylaxis with ganciclovir (GCV) on HCMV replication in LoM. GCV was administered once daily 2 d before and 14 d after inoculation of HCMV TB40/E expressing luciferase ( Fig. 2n ). HCMV replication was monitored over time by measuring luciferase activity. By 4 d postexposure, HCMV levels were ~66% lower in the human lung implants of GCV-treated LoM (mean 3.36 × 10 5 ± 1.61 × 10 5 s.e.m. radiance) compared with untreated controls (mean 1.00 × 10 6 ± 2.90 × 10 5 s.e.m. radiance) ( Fig. 2n ). HCMV levels continued to decline over time in GCV-treated LoM.
At the end of the GCV treatment course (14 d post-HCMV exposure), HCMV levels were ~2 logs lower in the lung implants of GCV-treated LoM (mean 1.48 × 10 5 ± 4.96 × 10 4 s.e.m. radiance) compared with untreated LoM (mean 8.99 × 10 6 ± 5.02 × 10 6 s.e.m. radiance) ( Fig. 2n) . Surprisingly, after GCV treatment was discontinued, HCMV levels continued to decline. By 25 d post-HCMV exposure (11 d after the last GCV dose), HCMV levels in the lung implants of GCV-treated LoM were further reduced by ~40% (mean 9.25 × 10 4 ± 2.65 × 10 4 s.e.m. radiance) and significantly lower than untreated controls (mean 3.27 × 10 7 ± 1.69 × 10 7 s.e.m. radiance) ( Fig. 2n ). Together, these results demonstrate the ability of LoM to sustain replication of several clinically relevant human pathogens and to serve as a platform for the in vivo testing of existing and novel antimicrobials.
HCMV gene expression is consistent with lytic replication. In healthy individuals, HCMV establishes a life-long latent infection.
In immune-suppressed individuals such as transplant and AIDS patients, HCMV can reactivate, resulting in uncontrolled lytic replication causing a multi-organ cytomegalovirus (CMV) syndrome 43 . Therefore, novel antivirals are needed that can inhibit HCMV lytic replication in vivo to ameliorate clinical symptoms of CMV disease. Since natural infections are typically asymptomatic and undiagnosed, the profile of HCMV genes expressed during lytic replication in vivo has not been determined on a genome-wide scale due to the difficulty of obtaining acutely infected samples. To define the complement of HCMV genes expressed in human tissue in vivo, we injected cell-free HCMV TB40/E into the human lung implants of LoM. HCMV double-stranded complementary DNA ((ds)cDNA) was enriched with biotinylated probes spanning both strands of the entire HCMV genome and next generation sequencing used to measure viral gene expression. Using this approach, we were able to measure the complement of viral genes expressed in vivo in human tissue during lytic replication. Results revealed widespread HCMV gene expression spanning the viral genome, consistent with robust lytic replication ( Supplementary Fig. 4 ). Expression of known lytic genes encoding IE proteins IE1 (UL123) and IE2 (UL122), early proteins (UL44 and UL38), and late proteins pp65 (UL83) and pp71 (UL82) were detected. By contrast, expression of UL138, a wellcharacterized latency gene, was not observed. These results serve as proof-of-principle of the utility of LoM to investigate key aspects of HCMV replication in human lung tissue in vivo.
The human innate and adaptive immune system of BLT-L mice.
We generated an in vivo model with human lung implants and an autologous human immune system by constructing BLT mice with autologous human lung implants (BLT-L humanized mice). BLT-L mice were constructed by surgically implanting (1) autologous human thymus and liver tissue under the kidney capsule and (2) human lung tissue subcutaneously into the back of the same preconditioned (irradiated) immunodeficient mouse followed by bone marrow transplantation with autologous human hematopoietic stem cells ( Fig. 3a) . Over time, BLT-L mice developed human lung implants and robust levels of human hematopoietic cells (hCD45 + ) in peripheral blood (PB) that were sustained for at least 8 months (last time analyzed) (Fig. 3b ). The PB of BLT-L mice was reconstituted with human myeloid cells, B cells and T cells, including CD4 + and CD8 + T cells ( Supplementary Fig. 5 ).
In addition to human epithelial, endothelial and mesenchymal cells (Fig. 3c ), human lung implants of BLT-L mice contained human innate and adaptive immune cells ( Fig. 3d ). Ex vivo stimulation of these cells with phorbol myristate acetate (PMA)/ionomycin or LPS demonstrated their broad capacity for human cytokine (pro-inflammatory and anti-inflammatory) and chemokine production (Supplementary Table 2 ). The human hematopoietic cells present in the human lung implants of BLT-L mice (hCD45 + , mean 72.5% ± 5.5% s.e.m.; range 27.4-90.4%) included human myeloid cells (hCD33 + , mean 15.2% ± 3.0% s.e.m.; range 0.5-42.8%), B cells (hCD19 + , mean 7.5% ± 1.7% s.e.m.; range 0.4-22.2%) and T cells (hCD3 + , mean 63.4% ± 4.6% s.e.m.; range 26.9-92.3%) ( Fig. 3e ). No significant difference in human myeloid cell, B-cell or T-cell levels was observed between the human lung implants and mouse lung of BLT-L mice ( Supplementary Fig. 6 ). CD4 + and CD8 + human T cells were present in the human lung implants of BLT-L mice. Human CD4 + T-cell levels were significantly lower (P = 6.472 × 10 -7 ) and CD8 + T-cell levels were significantly higher (P = 0.0004) in the human lung implants of BLT-L mice compared with the mouse lung. The CD4/CD8 T-cell ratio (mean 2.2 ± 0.17 s.e.m.; range 0.93-3.42) in human lung implants ( Fig. 3e ) was similar to that observed in humans 44 . No difference in T-cell activation was observed ( Supplementary Fig. 6 ). Memory (CD45RO + ) CD4 + and CD8 + T cells were present in the human lung implants of BLT-L mice, the majority of which expressed an effector memory phenotype (CCR7-negative) (CD4 + T cells, mean 87.2% ± 1.97% s.e.m.; range 81.8-90.8% and CD8 + T cells, mean 97.1% ± 0.44% s.e.m.; range 96.1-97.9%) ( Supplementary Fig. 7a,b ). We also identified the presence of CD4 + (mean 25.4% ± 3.58% s.e.m.; range 18.5-35.5% of memory CD4 + T cells) and CD8 + (mean 38.5% ± 7.11% s.e.m.; range 21.0-51.8% of memory CD8 + T cells) tissue-resident memory T cells (CD45RO + CD69 + ) in the human lung implants of BLT-L mice, as observed in humans ( Supplementary Fig. 7c,d) 44 . Similar to BLT mice, in addition to the human lung implant, human hematopoietic cells were systemically distributed throughout the animals including primary and secondary immune tissues (bone marrow, human thymic implant, spleen and lymph nodes), effector sites and mucosal tissues (lung, liver, gastrointestinal tract and female reproductive tract) of BLT-L mice (Fig. 3f ). Innate and adaptive human immune cells were present in all tissues analyzed ( Supplementary Fig. 7e ).
Immune-mediated control of HCMV infection in BLT-L mice.
LoM and BLT-L mice were inoculated with HCMV TB40/E expressing luciferase 45 . HCMV replication was detectable in the human lung implants of LoM and BLT-L mice at 4 d postinoculation (Fig. 4a ). In LoM, robust HCMV replication was maintained up to 5 weeks postinoculation (last time point analyzed) (Fig. 4a ). In contrast, in BLT-L mice HCMV replication began to decline by 11 d postinoculation ( Fig. 4a ). Luciferase activity in BLT-L mice was significantly lower compared with LoM (Fig. 4a ). HCMV replication in BLT-L mice continued to decline over time (Fig. 4a) . Specifically, luciferase activity in the human lung implants of BLT-L mice at week 4 (mean 5.10 × 10 4 ± 2.25 × 10 4 s.e.m. radiance; range 2.68 × 10 4 -8.4 × 10 4 radiance) and week 5 (mean 6.46 × 10 4 ± 8.08 × 10 3 s.e.m. radiance; range 5.5 × 10 4 -7.47 × 10 4 radiance) postinoculation approached baseline levels (mean 2.34 × 10 4 radiance) and was significantly lower compared with LoM (Fig. 4a ). These results demonstrate that while the human lung implants of LoM and BLT-L mice support HCMV infection, in contrast to LoM, HCMV replication is efficiently controlled in BLT-L mice.
Levels of human cytokines and chemokines were analyzed in BLT-L mice pre-and post-HCMV TB40/E inoculation. At 4 d postinoculation, increased plasma levels of human GM-CSF, IFN-γ, IL-6, IL-8, MDC, IP-10, GRO and MCP-1 were detected ( Supplementary Fig. 8 ). HCMV-specific human antibody and T-cell responses were examined in BLT-L mice exposed to the three different HCMV strains: TB40/E, AD169 and ADrUL131. AD169 is a well-characterized fibroblast-adapted laboratory strain that lacks the UL131 gene. ADrUL131 is an AD169 derivative in which UL131 is repaired [46] [47] [48] . PB plasma was collected longitudinally to measure HCMV-specific IgM levels. HCMV IgM levels in humans peak between 1 and 3 months after primary infection 49 . Consistent with human infection, HCMV IgM was detected as early as 14 d following TB40/E or ADrUL131 inoculation in different BLT-L cohorts (that is, mice generated from different human donor tissues) ( Fig. 4b and Supplementary Tables 3 and 4 ).
To examine whether BLT-L mice induced CD8 + T-cell responses to HCMV that are immunoprevalent in human infection, BLT-L donor tissue was HLA-typed (Supplementary Table 3 ) and reactivity to HCMV pentamers examined. HCMV infection induced classically HLA Ia-restricted HCMV pp65-specific CD8 + T cells in the human lung implant as early as 12 d following HCMV TB40/E inoculation (Fig. 4c,d and Supplementary Table 4 ). The functionality of these T cells was also examined by HCMV pentamer overlay of cells (mononuclear cells pooled from the liver of three mice, cohort B) stimulated with mitogen ( Fig. 4d ). All HCMV pentamerreactive CD8 + T cells (red events, Fig. 4d right panel) were functional, producing the antiviral cytokine IFN-γ or both IFN-γ and the lytic granule marker CD107a.
Additional functional studies were performed using either ex vivo IFN-γ enzyme-linked immunospot (ELISpot) assays or intracellular cytokine staining (ICS), in which irradiated autologous B-cell lines were used to present HCMV peptide epitopes or peptide pools (HCMV pp65 or IE1) to tissue cells ( Supplementary Table 4 ). Here, we compared TB40/E and AD169 infection. Similar to TB40/E, AD169 induced T-cell responses to HLA-A and HLA-B pp65 peptide epitopes in BLT-L mice ( Fig. 4e and Supplementary Table 5 ). Both strains also consistently induced T-cell responses to HCMV IE1 as early as 14 d postexposure (Fig. 4f,g and Supplementary Table 5 ). IE1 is an immunoprevalent HCMV protein not found in virions but expressed after infection 42 . The detection of IE1-specific responses is consistent with the in vivo lytic replication of HCMV observed in Fig. 4a . HCMV-specific T-cell responses were detected in the human lung implant of BLT-L mice and systemically (liver and mouse lung) ( Fig. 4c-h) and were maintained for up to 125 d (last time point analyzed) ( Fig. 4h and Supplementary Table 4 ). Full details of T-cell reactivity are provided in Supplementary Table 4 .
Our data demonstrating IE1-specific T-cell responses in BLT-L mice and a progressive decline in TB40/E-luciferase activity indicate that these mice were productively infected with HCMV, but, unlike LoM (Figs. 2k-n and 4a and Supplementary Fig. 9 ), virus replication was controlled. HCMV DNA was readily detected in the human lung implants of all BLT-L mice analyzed <14 d postexposure ( Supplementary Table 6 ). However, consistent with the immunemediated virological control observed in BLT-L mice (Fig. 4a ), only 55% of human lung implants analyzed between 14-34 d postexposure, and none of the human lung implants analyzed after 34 d postexposure, had detectable levels of viral DNA (Supplementary Table 6 ). HCMV DNA was rarely detected in other tissues analyzed (12 of 135) (Supplementary Table 6 ), suggesting that HCMV dissemination to peripheral tissues was limited and/or replication controlled.
Re-exposure boosts antibody and T-cell responses to HCMV.
To mimic the ongoing antigenic exposure that occurs during chronic HCMV infection, we investigated the effect of repeated HCMV exposure on host immune responses. Mice were inoculated with 3-4 doses of HCMV TB40/E or AD169.
Over 90% (22 of 24) of mice had detectable HCMV-specific IgM following repeated (3-4 times) HCMV exposure, regardless of the infecting HCMV strain (Fig. 5a ). HCMV-specific IgG was detected in ~73% (16 of 22) of re-exposed BLT-L mice (Fig. 5b) , demonstrating efficient class switching. Plasma samples collected from BLT-L mice repeatedly exposed to TB40/E and with detectable HCMV-specific IgM and IgG possessed neutralizing activity, reducing HCMV infection in vitro by up to 91% ( Supplementary Fig. 10 ). The time from first HCMV exposure to antibody testing differed between singly or multiply exposed mice (1 dose: mean 48 d postexposure, range 12-125 d; and 3-4 doses: mean 77 d postexposure, range 42-120 d). We cannot therefore exclude that time, in addition to repeated antigen exposure, contributed to class switching. However, TB40/E failed to induce HCMV-specific IgG 125 d after a single exposure ( Fig. 5b and Supplementary Table 4 ), despite the presence of a detectable HCMV-specific CD8 + T-cell response (Fig. 4h) .
HCMV infection induces robust and sustained CD4 + T-cell responses 50 . In BLT-L mice inoculated once with HCMV, we were unable to detect HCMV-specific CD4 + T-cell responses by ICS (data not shown). However, following repeated HCMV exposure, IE1-specific CD4 + T-cell cytokine responses were detected in the human lung implant and liver of BLT-L mice, suggesting that repeated antigen exposure induced or augmented antigen-specific CD4 + T-cell responses (Fig. 5c ). IE1-specific CD8 + T-cell responses measured by ICS were detected more frequently in repeatedly HCMV-exposed mice than in singly exposed BLT-L mice (Fischer's exact, two-tailed P = 0.039) (Fig. 5d,e and Supplementary Tables 4, 7 and 8) . Repeated HCMV exposure also induced stronger HCMV-specific CD8 + T-cell responses across tissues (Figs. 4h and 5d-f) , producing T-cell responses consistent with those reported in human HCMV infection [51] [52] [53] [54] . Increases in pentamer reactivity were also observed. Classically restricted HCMV-specific CD8 + T cells in repeat exposure BLT-L mice approached 2% of all CD8 + T cells (Fig. 5f ), between 4-and 15-fold greater than pentamer frequencies observed following a single exposure (Fig. 4c,d and data not shown). Full details of immune reactivity following repeated HCMV inoculation are provided in Supplementary Tables 7 and 8 .
Although BLT-L mice were exposed to multiple doses of TB40/E or AD169, HCMV DNA was only detected in the human lung implants of 9 of 18 mice analyzed (2 TB40/E-and 7 AD169-exposed BLT-L mice) ( Supplementary Tables 9 and 10 ). HCMV DNA was rarely detected in tissues other than the human lung implants (3 of 108 tissues analyzed) and was not detected in PB ( Supplementary  Tables 9 and 10 ), suggesting strong immune control of HCMV replication in vivo.
Discussion
To extend the breadth of human pathogens that can be studied using humanized mice, we validated two models, LoM and BLT-L mice, which provide human lung tissue as an in vivo target for human pathogens either without (LoM) or with (BLT-L mice) an autologous systemic human immune system. The engraftment levels of human immune cell types in BLT-L mice are similar to previously reported BLT mice [55] [56] [57] . The subcutaneously implanted human lung tissue expands and develops into lung implants containing human epithelial, endothelial and mesenchymal cells and a vasculature of human origin. Located just underneath the skin, the lung implants can be readily accessed and imaged.
Using LoM, we demonstrated that the human lung implants are susceptible to five diverse emerging and clinically relevant human pathogens (MERS-CoV, ZIKV, mycobacteria, RSV and HCMV) without further engineering of the pathogens or the host. However, it is possible that a respiring lung will have different host gene expression profiles, which could alter the replication conditions of some pathogens. We next demonstrated that pre-exposure prophylaxis with GCV can effectively control HCMV replication in LoM and performed an in vivo transcriptome analysis of lytic HCMV infection. In the future, transcriptome analyses of the pathogen and host may identify new drug targets and host factors that modulate infection.
HCMV infection in BLT-L mice produced acute virus kinetics that reflected lytic replication, consistent with those reported in humans. With the onset of adaptive humoral and T-cell responses, HCMV replication in BLT-L mice declined to background levels. Whereas HCMV DNA was detected in all exposed LoM, HCMV DNA was only detected in BLT-L mice during the first 2 weeks postinfection, consistent with the strong virological immune control observed. CD8 + T-cell responses were detectable in the lung implant as early as 12 d postinoculation to multiple epitopes including the IE1 and pp65 proteins, which are targeted in 50% of human patients 58 . HCMV-specific T cells were detected systemically in the liver and mouse lung. HCMV-specific CD8 + T-cell responses were detected up to 125 d following inoculation. The induction of a systemic antigen-specific immune response in BLT-L mice, combined with our data demonstrating the production of human cytokines/chemokines following ex vivo mitogen stimulation of human immune cells isolated from the lung implants, demonstrates the functionality of the human immune cells that repopulate the lung implants.
Mimicking the ongoing antigenic exposure that occurs during chronic HCMV infection, multiple exposures to HCMV resulted in a more robust HCMV-specific antibody and T-cell response in BLT-L mice. We readily detected HCMV-specific IgG in BLT-L mice re-exposed to TB40/E or AD169, suggesting that repeat antigen stimulation facilitates human IgG class switching. Multiple HCMV exposures also induced a robust HCMV-specific T-cell response. Natural HCMV infection in humans elicits a life-long CD4 + and CD8 + T-cell response and very high reactivity (80-100%) to IE1 and pp65 proteins 58, 59 . We readily observed IE1-specific CD4 + T cells in multiple tissues of BLT-L mice repeatedly exposed to HCMV. The magnitude of the HCMV-specific CD8 + T-cell response was also increased in BLT-L mice exposed to multiple doses of HCMV and reached levels comparable to humans [52] [53] [54] 60, 61 . The fact that repeated exposure can be used to broaden the immunoprevalence of T-cell responses in BLT-L mice suggests that the model might be useful in vaccine testing.
We did not observe an HCMV-specific CD8 + T-cell response or HCMV-specific IgG in cohort F of BLT-L mice, despite multiple exposures to TB40/E. This cohort (F) was homozygous across all class Ia and II alleles (Supplementary Table 3 ). HCMV induced low levels of IgM but no class switching was observed ( Fig. 5a,b , square symbols). Despite a 111-120 d follow-up (postfirst HCMV exposure), no IE1-specific T-cell IFN-γ + /CD107a + responses were detected ( Fig. 5e and Supplementary Table 7 ). T cells and myeloid dendritic cells (mDCs) in this cohort were functional; specifically, mitogenic stimulation of T cells induced potent cytokine production and degranulation, and autologous mDCs induced a mixed-lymphocyte reaction when cocultured with allogeneic peripheral blood mononuclear cells (data not shown). These results suggest that a limited repertoire of HLApresented viral peptides impedes the generation of antigen-specific adaptive immune response in vivo.
BLT-L mice generate antigen-specific humoral and cell-mediated immune responses that control pathogen replication in vivo. These results validate BLT-L mice as an in vivo platform to study the replication, pathogenesis and immunogenicity of human pathogens in the context of a functional systemic human immune system. In this regard, BLT-L mice would support the type of direct, systematic and sophisticated in vivo experimentation that is characteristic of rodent models but cannot be performed in humans. Our results also support BLT-L mice as a model for the in vivo evaluation of human immune therapies, including vaccines, especially for diseases with a strict species tropism.
In summary, we have developed two humanized mouse models that support infection and replication of important human viral and bacterial pathogens. LoM and BLT-L mice could be used to study other human pathogens that target the lung (for example, enterovirus D68, adenovirus type 7, influenza virus, rhinovirus and metapneumovirus), accelerating the in vivo testing of preventative and therapeutic approaches for these agents. Our analysis of implant vascularization using 3D ultrasound acoustic angiography, a noninvasive technique to visualize microvasculature, also suggests that this technology can be used for monitoring angiogenesis and vascularization in other systems. Our results also suggest that developing additional in vivo humanized mouse models for human pathogens with tropism for other tissues might be possible and might enhance the precision of humanized mouse models for biomedical research.
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LoM were fixed in 10% formalin for >7 d at 4 °C, embedded in paraffin, sectioned (5 µm) and stained with MERS-CoV nucleocapsid polyclonal antibody (Life Sciences Reporting Summary). Tissue sections were also stained with appropriate isotype-negative control antibodies. Tissue sections for immunohistochemistry were imaged on a Nikon Eclipse Ci microscope using Nikon Elements BR software (version 4.30.01) with a Nikon Digital Sight DS-Fi2 camera and brightness and contrast were adjusted on whole images in Adobe Photoshop (CS6). Tissue sections for immunofluorescence were imaged on an Olympus BX61 upright wide-field microscope using Improvision's Velocity software (version X) with a Hammatuse ORCA RC camera. Brightness and contrast were adjusted on whole images using ImageJ software (version 1.51C). In Fig. 2b,d ,h,m, pseudocoloring was used to depict MERS-CoV, ZIKV, RSV and HCMV antigens in green and human cell types in magenta. In Figs. 1i,j and 2i and Supplementary Fig. 1b , where red/green fluorescent images were originally captured, the red fluorescent signal was digitally altered to improve visualization by color-blind readers by adjusting the red channel hue by −45 using Adobe Photoshop (CS6).
Analysis of human immune cell reconstitution.
Human immune cell reconstitution in the PB and tissues of BLT-L mice were analyzed by flow cytometry. Mononuclear cells (MNCs) were isolated from tissues collected from BLT-L mice by passage through a cell strainer and red blood cell lysis as previously described 13, 14, [62] [63] [64] . The human lung implants, mouse lung, liver and female reproductive tract were enzymatically digested before passing tissue through a cell strainer. Liver and mouse lung MNCs were purified with a Percoll gradient. MNCs were isolated from the gastrointestinal tract (small and large intestines) lamina propria layer with an enzymatic digest as previously described. Before antibody (Life Sciences Reporting Summary) incubation Ig-binding sites were blocked. The antibody panels were as follows: CD45-APC, CD19-PE, CD3-FITC and CD4-PerCP (panel 1); CD45-APC, CD19-PE-Cy7, CD33-PE, CD3-FITC, CD4-APC-H7 and CD8-PerCP (panel 2); CD45-APC, CD19-PE-Cy7, CD33-PE, CD3-FITC and CD8-APC-Cy7 (panel 3); CD45-V500, CD3-AlexaFlour 700 or APC-R700, CD4-BV605, CD8-APC-Cy7, CD45RO-FITC or negative control mouse IgG2ak-FITC, CD69-PE or negative control mouse IgG1k, CCR7-PE-Cy7 or negative control rat IgG2aak, HLA-DR-PerCP or negative control mouse IgG2ak-PerCP, and CD25-APC or negative control mouse IgG1k-APC (panel 4); and CD45-V500, CD19-PE-Cy7, CD3-AlexaFlour 700 or APC-R700, CD4-APC-H7, CD8-FITC, CD45RA-Pacific Blue or negative control mouse IgG1ak-Pacific Blue, CD27-PE or negative control mouse IgG1k-PE, HLA-DR-PerCP or negative control mouse IgG2ak-PerCP, and CD38-APC or negative control mouse IgG1k-APC (panel 5). Following antibody incubation, PB was treated with 1X BD FACS lysing solution (BD Biosciences) to remove red blood cells. Samples were then washed and fixed with PFA. Data were acquired on a BD LSRFortessa or FACSCanto instrument and analyzed with FACSDiva software (version 6.1.3).
Analysis of human cytokine/chemokine production.
MNCs were isolated from BLT-L mouse (n = 6 mice and 12 lung implants, data represent two experiments) human lung implants. Human lung implants were enzymatically digested before passing tissue through a cell strainer and MNCs were purified with a Percoll gradient. MNCs were pooled from the lung implants of 3 mice (n = 6 lung implants) and cultured (7.8 × 10 5 cells per well of a 48-well plate) for 4 h in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin (untreated control, 1 well per experiment) or media supplemented with PMA (25 ng ml −1 )/ Ionomycin (250 ng ml −1 ) (1 well experiment 1, and 2 wells experiment 2) or with LPS (100 ng ml −1 , E. coli O55:B5, Sigma) (1 well per experiment). Cell culture supernatant was collected at 4 h. Cells were also isolated from the human lung implant of LoM (n = 1 mouse, 2 human lung implants, represents one experiment) following a 24 h enzymatic digest (1% Protease XIV/0.01% DNase solution diluted 1:19 in F12 medium supplemented with amphotericin and gentamicin) at 4 °C. Cells (1 × 10 6 cells per well) were cultured overnight in bronchial epithelial growth medium (BEGM) 67 supplemented with 10% FBS in wells of a collagen-coated 48-well plate (5.6 μg cm −2 human placental collagen type IV). Wells were washed to remove nonadherent cells and then cells cultured in BEGM + 10% FBS medium alone (untreated control) or supplemented with LPS (100 ng ml −1 , E. coli O55:B5, Sigma) (3 wells per condition/lung implant). Cell culture supernatant was collected at 24 h. Plasma was isolated from PB collected from BLT-L mice (n = 10 mice, represents three experiments) 3 d before and 4 d post-HCMV-TB40/E (2.2 × 10 6 tissue culture infectious dose (TCID) 50 ) inoculation into human lung implants. Human cytokine/ chemokine levels in cell culture supernatant and plasma were measured using a Milliplex MAP kit (Millipore no. HCYTMAG-60K-PX41, limit of detection: 3.2 pg ml −1 ) on a Luminex MagPix instrument. Samples were run undiluted in singular wells. The following 41 human analytes were measured: Eotaxin/CCL11, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGF-α, TNF-α, TNF-β, VEGF and EGF. BEGM contains human EGF; therefore, EGF levels were not reported. No statistical methods were used to predetermine sample size. No randomization was used to determine how samples/animals were allocated to experimental groups or processed. Investigators were not blinded to group allocations or when assessing outcomes. For all statistical comparisons P < 0.05 was considered significant. All statistical tests were exact. A two-tailed Mann-Whitney test was used to compare luciferase activity in the human lung implants of LoM and BLT-L mice (Fig. 4a ) and human immune cell levels in the mouse lung and human lung organoids of BLT-L mice ( Supplementary Fig. 6 ). A two-tailed Fischer's exact test was used to compare the incidence of HCMV-specific human IgM, IgG and CD8 + T cells in BLT-L mice exposed to one or multiple doses of HCMV ( Figs. 4 and 5) . Human cytokine and chemokine levels pre-and post-HCMV inoculation were compared with a two-tailed Wilcoxon matched-pairs signed rank test ( Supplementary Fig. 8 ).
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Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
